Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Houede Nadine

Professeur des Universités

University of Montpellier

France

Research Interests

Explore related searches

Professors in France

About

Professor Houede Nadine is a faculty member at Université de Montpellier in France. Her research focuses on urothelial cancers, specifically the management of locally advanced and metastatic cases, and the efficacy of neoadjuvant therapies. Recent publications include studies on the impact of treatment protocols on long-term survival and quality of life of prostate cancer patients.

Articles (6)

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2020

Year:

2020

Collaborators (2)

Aurélie bertaut

Head of methodology and biostatistic unit

Centre Georges-François Leclerc

FRANCE

View details

Yohann Loriot

Institut Gustave Roussy

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Houede Nadine

Research Interests

Explore related searches

About

Articles (6)

ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette–Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)

Full enrollment results from cohort 1 of the phase III randomized THOR trial of erdafitinib versus chemotherapy in FGFR-altered advanced urothelial carcinoma

Comment optimiser la prise en charge des patients de cancers urothéliaux localement avancés et ou/métastatique ?

Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors

Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case-control study

Collaborators (2)

Aurélie bertaut

Yohann Loriot

Make your next move.